Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Price History
|
Ratios
|
Insiders
Bullboard - Stock Discussion Forum
Thiogenesis Therapeutics Corp
V.TTI
Alternate Symbol(s):
TTIPF
Healthcare
Biotechnology
Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. Its lead product candidate is TTI-0102, a prodrug that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated...
steatohepatitis, and rett syndrome. The company is headquartered in Toronto, Canada.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Bullboard (TSXV:TTI)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
Next
(24)
•••
SkywalkerofLuke
X
Post by
SkywalkerofLuke
on Dec 05, 2025 3:03pm
TTI Initiating Phase 3 Clinical Trials of TTI-0102
Posted on behalf of Thiogenesis Therapeutics Corp. - Last week Thiogenesis Therapeutics Corp. (TTI.v TTIPF) announced plans to initiate a Phase 3 pivotal clinical trial of its lead compound TTI-0102
...more
•••
Jonathon Brown
X
Post by
Jonathon Brown
on Dec 04, 2025 6:08am
Buzz on the Bullboards: Cannabis stock split, major financing, and battery breakthrough
Inflation concerns, lofty valuations, and growing uncertainty around returns from have prompted investors to reassess their AI exposure.
read article.
Scaling for long-term success: A new era in gold development
posted Dec 16, 2025 9:00am by
Vista Gold Corp.
-
|
Backed by years of technical expertise and strategic discipline, Mt Todd has emerged as one of the most compelling undeveloped gold assets globally. A recently completed feasibility study signals a pivotal shift in strategy ...read more
(159)
•••
1StockInformer
X
Post by
1StockInformer
on Nov 25, 2025 7:32pm
TTI Shares Phase 3 Nephropathic Cystinosis Plans
Posted on behalf of Thiogenesis Therapeutics, Corp. - Thiogenesis Therapeutics, Corp. (Ticker: TTI.v or TTIPF for US investors) develops next-generation sulfur-based prodrugs targeting rare
...more
(109)
•••
MarketMakerss
X
Post by
MarketMakerss
on Nov 24, 2025 1:34pm
Phase 3 Trial of TTI-0102 Announced Today
Posted on Behalf of Thiogenesis Therapeutics Corp. - Today, Thiogenesis Therapeutics (TTI.v TTIPF) announced plans to initiate a Phase 3 pivotal clinical trial in 2026 for its lead drug candidate TTI
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 24, 2025 9:01am
New Press Release - Thiogenesis Therapeutics Expands on Plans for Phase 3 Pivotal Trial of TTI-0102 in Nephropathic Cystinosis
IND expected in early 2026; TTI-0102 designed to improve tolerability & simplify dosingSan Diego, California--(Newsfile Corp. - November 24, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing next...
read article.
(191)
•••
JazzLover444
X
Post by
JazzLover444
on Nov 20, 2025 4:40pm
Phase 2 Highlights (MELAS)
Thiogenesis Therapeutics (TTI.v | TTIPF): Positive Phase 2 MELAS Data Strengthens Rare-Disease Pipeline Momentum Posted on behalf of Thiogenesis Therapeutics, Corp: Thiogenesis Therapeutics reported
...more
(159)
•••
1StockInformer
X
Post by
1StockInformer
on Nov 13, 2025 6:08pm
TTI.v Details Pipeline Advancements and Early Trial Results
Last week, Thiogenesis Therapeutics Corp. (TTI.v or TTIPF for US investors), a clinical-stage biotechnology company focused on sulfur-based approaches for mitochondrial conditions, published an update
...more
(191)
•••
JazzLover444
X
Post by
JazzLover444
on Nov 12, 2025 5:41pm
Encouraging Phase 2 MELAS Data
Thiogenesis Therapeutics (TSXV: TTI | OTCQX: TTIPF): Encouraging Phase 2 MELAS Data & Pipeline Momentum Across Multiple Rare Diseases Thiogenesis Therapeutics reported positive interim Phase 2
...more
(159)
•••
1StockInformer
X
Post by
1StockInformer
on Nov 06, 2025 7:25pm
TTI Reports Positive Interim Phase 2 MELAS Trial Data
Thiogenesis Therapeutics Corp. (Ticker: TTI.v or TTIPF for US investors), a San Diego–based clinical-stage biotech company developing sulfur-based therapies for mitochondrial disorders, recently
...more
(61)
•••
bmreed
X
Post by
bmreed
on Nov 06, 2025 4:03pm
Live Webinar w $TTI CEO Brook Riggins - Thu, Nov 13 @ 1PM ET
Live CEO Webinar - Thiogenesis Therapeutics $TTI CEO Brook Riggins Thursday, November 13th at 1pm ET / 10am PT Q&A with Radius Research Register Here - https://us02web.zoom.us/webinar
...more
(109)
•••
MarketMakerss
X
Post by
MarketMakerss
on Nov 04, 2025 4:26pm
Positive Interim Phase 2 Results for MELAS Reported
TODAY: Thiogenesis Therapeutics (TTI.v TTIPF) Reports Positive Interim Phase 2 Results for TTI-0102 in MELAS and Expands Late-Stage Pipeline Today, Thiogenesis Therapeutics (TTI.v TTIPF
...more
(159)
•••
1StockInformer
X
Post by
1StockInformer
on Oct 24, 2025 7:14pm
TTI: Trial Momentum, Regulatory Milestones & >$4M Financing
Thiogenesis Therapeutics Corp. (Ticker: TTI.v or TTIPF for US investors) is a San Diego–based clinical-stage biopharmaceutical company developing sulfur-based therapeutics to treat pediatric diseases
...more
(191)
•••
JazzLover444
X
Post by
JazzLover444
on Oct 21, 2025 6:48pm
TTI: Advancing Pediatric & Metabolic innovation
Thiogenesis Therapeutics: Advancing Pediatric & Metabolic Innovation $TTI.V | $TTIPF Large-cap pharma’s renewed interest in metabolic and genetic disease is
...more
(109)
•••
MarketMakerss
X
Post by
MarketMakerss
on Oct 15, 2025 6:02pm
Renewed Buying Spree in Metabolic & Genetic Diseases
Large-cap pharma’s renewed buying spree in metabolic and genetic disease continues, with Novo Nordisk’s $5.2B acquisition of Akero Therapeutics (AKRO) underscoring surging interest in MASH and
...more
(159)
•••
1StockInformer
X
Post by
1StockInformer
on Oct 10, 2025 6:48pm
MASH Treatment Space Momentum Builds w/ $5.2B Akero Buyout
The biotech sector continues to draw attention as large-cap acquirers target companies advancing next-generation metabolic and genetic therapies. This week, Novo Nordisk announced the acquisition
...more
(109)
•••
MarketMakerss
X
Post by
MarketMakerss
on Oct 03, 2025 8:02pm
Strategic Leadership Spotlight
Strategic Leadership Spotlight - Thiogenesis Therapeutics (TTI.v TTIPF) Advancing a late-stage pipeline across orphan and pediatric diseases with no approved therapies, Thiogenesis
...more
Prev
1
2
3
4
5
6
7
8
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
Featured News Links
A waste-to-fuel development focused on producing low-carbon renewable fuels
Mt Todd has emerged as one of the most compelling undeveloped gold assets globally
Environmental technology company enters a new strategic phase focused on scale and profitability
A company intending to uplist to the New York Stock Exchange reports strong third-quarter results